

Order Form for High Risk Vaccine One form per client

Name of Client:		Date of Birth:	Age:	
			YYYY/MM/DD	
Gender:	Ontario Health Card Number	:	HCP Phone Number:	
🗆 Male 🗆 Female 🗆 Other				
Health Care Practitioner Name (HCP):		HCP Fax Number:		
Facility Name: HCP and/		or Designate Signature:		
Date of Request: YYYY/	MM/DD			
Date of scheduled appointment: YYYY/MM/DD				

Please note, you must complete and fax this form immediately to the Porcupine Health Unit in Timmins at 705-360-7308 once the vaccine is administered. (You will receive a copy of this form with the vaccine for you to fax.)

Vaccine Administration				
Date Administered:	Site Administered:	Type of Vaccine:	Lot #	
YYYY / MM / DD			Expiry Date:	
Date Administered:	Site Administered:	Type of Vaccine:	Lot #	
YYYY / MM / DD			Expiry Date:	

*For each vaccine being requested, check all criteria(s) that apply for this client:

Haemophilus infuenzae type b - Act-Hib® (6571-3255-0)	Dose being requested: Dose 1 Dose 2 Dose 3
Eligibility - ≥ 5 years with:	 Bone marrow or solid organ transplant recipient (1 dose)
Hematopoietic stem cell transplant recipient (HSCT) *(3 doses)	Lung transplant recipient (1 dose)
 Functional or anatomic asplenia (1 dose) Immunocompromised related to disease or therapy (1 dose) 	 Cochlear implant recipient (pre/post implant) (1 dose) Primary antibody deficiency (1 dose)

Meningococcal B - Bexsero[®] (6571-3314-0) Dose being requested: Dose 1 Dose 2 Dose 3 Dose 4

Eligibility – Age 2 months to 17 years with:

Functional or anatomic asplenia

□ Complement, properdin, factor D deficiency, or primarily antibody deficiency

□ Cochlear implant recipient (pre/post implant)

□ Those born in 2002, 2003, 2004 or 2005 (eligible until December 31, 2023)

□ Acquired complement deficiency (e.g., receiving eculizumab)

□ HIV

Meningococcal C-ACYW135 Dose being requested: Dose 1 Dose 2 Dose 3 Dose 4 Booster

 \Box Nimenrix[®] (6571-3370-0) <u>2 to 55 years</u> or <u>> 56 years of age to replace menomune</u>

□ **Menveo[®]** (6571-2017-0) 9 to 23 months of age

Eligibility - 9 months to 55 years or ≥ 56 years

Functional or anatomic asplenia

□ Complement, properdin, factor D deficiency, or primarily antibody deficiency

□ Cochlear implant recipient (pre/post implant)

□ Acquired complement deficiency (e.g., receiving eculizumab)

□ HIV

Hepatitis A (Avaxim [®] /Havrix [®] /VAQTA [®])	Dose being requested: Dose 1 Dose 2
□ adult (6571-3257-0) □ paediatric (6571-3256-0)	
Eligibility – \geq to 1 year with:	Persons engaging in intravenous drug use

□ Chronic liver disease (including Hepatitis B and C)

Men who have sex with men

Order Form for High Risk Vaccine One form per client

One form per client				
Human Papillomavirus Vaccine - Gardasil9 [®] (6571-3390-0)	Dose being requested: Dose 1 Dose 2 Dose 3			
Eligibility - ≤ 26 years of age who have <u>NOT</u> started a series already and who are: □ males born in 1993, 1994, 1995, 1996 or 1997 (eligible until December 31, 2024) □ men who have sex with men (MSM), including gay, bisexual and trans (those who identify as MSM)				
	sted: Dose 1 Dose 2 Dose 3 Dose 4 (for premature babies ONLY)			
□ paediatric (6571-3251-0) □ adult/adolescent 20 mcg (6	571-3243-0) 🛛 renal dialysis 40 mcg (6571-3324-1)			
 Eligibility - ≥ to 0 years of age: Infant born to HBV-positive carrier mothers: Premature infant weighing <2000 grams at birth (4 doses) Premature infant weighing ≥2000 grams at birth and full/post Household or sexual contact of chronic carrier or acute case (3 doses) Awaiting liver transplant (2nd and 3rd doses only) Men who have sex with men, individual with multiple sex partners, of Needle stick injury in a non-health care setting (3 doses) Child <7 years old whose family has immigrated from country of high hepatitis B carriers through their extended family (3 doses) Renal dialysis or disease requiring frequent receipt of blood products Individual engaging in intravenous drug use (3 doses) Chronic liver disease including hepatitis C (3 doses)) or history of a sexually transmitted disease (3 doses) a prevalence for hepatitis B and who may be exposed to s (eg., haemophilia) (2 nd and 3 rd doses only)			
Pneumococcal C-20 Valent – Prevnar-20 [®] (6571-4010-2)	Dose being requested: Dose 1			
 Use existing inventory if you have it and if the client meets criteria below ** Please refer to following HCP Fact Sheets for guidance on product to use, number of doses required, intervals and how to complete a vaccine series when other Pneumococcal products were used. HCP Fact Sheet: Pneumococcal conjugate vaccine for individuals aged 5-64 years at high risk for IPD for vaccine intervals. HCP Fact Sheet: Pneumococcal conjugate vaccines for children aged 6 weeks to 4 years. 				
 Asplenia (anatomical or functional), splenic dysfunction Congenital (primary) immunodeficiencies involving any part of the immune system, including B-lymphocyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (properdin, or factor D deficiencies), or phagocytic functions. HIV infection Immunocompromising therapy including use of long-term systemic corticosteroid, chemotherapy, radiation therapy, post-organ 	 Chronic renal disease, including nephrotic syndrome Chronic cardiac disease Chronic liver disease, including hepatitis B and C Chronic respiratory disease, excluding asthma, except those treated with high-dose corticosteroid therapy Chronic neurologic conditions that may impair clearance of oral secretions Diabetes mellitus 			

- Diabetes mellitus
- □ Cochlear implant recipients (pre/post implant)
- □ Chronic cerebral spinal fluid leak
- Residents of nursing homes, homes for the aged and chronic care facilities or wards
- □ Hematopoietic stem cell transplant (HSCT) (recipient)

Adverse Event Following Immunization (AEFI): Remember to report any AEFI's to the Porcupine Health Unit

transplant therapy, certain anti-rheumatic drugs and other

□ Malignant neoplasms, including leukemia and lymphoma

□ Solid organ or islet cell transplant (recipient)

□ Sickle-cell disease and other sickle cell hemoglobinopathies

immunosuppressive therapy

□ Hepatic cirrhosis due to any cause